Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases
Conditions
Keywords
Drug therapy
Brief summary
The purpose of this non-interventional study (NIS) study is to assess further knowledge on the routine use of Entyvio in inflammatory bowel disease therapy, particularly the use in participants with CD and UC naive to biologics.
Detailed description
The drug being tested in this prospective, observational study is called vedolizumab. Vedolizumab (Entyvio) is being used to treat people who have CD or UC. This study will look in the routine use of vedolizumab in inflammatory bowel disease therapy in participants with CD or UC who did not receive a biologic treatment before. The study will enroll approximately 150 participants. All participants enrolled in this will belong to one observational group: Vedolizumab. Participants taking vedolizumab as per physician's prescription in routine clinical practice will be observed. This multi-centre trial will be conducted in Austria. The overall time to participate in this study is 2 years. Participant taking vedolizumab in routine clinical practice will make multiple visits to the clinic at Baseline, Week 20 and 52. Once a participant is switched to subsequent biologic treatment upon failing treatment with vedolizumab, the switching date will be considered as new baseline followed by visits at Week 20 and 52.
Interventions
None listed
Sponsors
Takeda
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1 Initiating vedolizumab for moderately to severely active UC or CD.
Exclusion criteria
1. Participant is enrolled in a clinical trial in which treatment for UC or CD is managed through a protocol, 2. Prior treatment with a biologic agent, 3. Any other reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With UC Achieving Clinical Response Based on Partial Mayo Score | Baseline up to 52 Weeks | Clinical response is defined as a decrease in the partial Mayo Score of at least 2 points and \>=25% from baseline, with an accompanying decrease in rectal bleeding subscore of \>=1 point from baseline or absolute rectal bleeding subscore of \<=1 point. Mayo score is an instrument designed to measure disease activity of UC. It consists of 3 subscores: stool frequency, rectal bleeding, and physician rating of disease activity, each graded from 0 to 3 with higher scores indicating more severe disease. These scores are summed to give a total score range of 0 to 9; where higher scores indicating more severe disease. Outcome measure is planned to be assessed in bio-naive participants who receive vedolizumab treatment. |
| Percentage of Participants With CD Achieving Clinical Response Based on Harvey-Bradshaw Index (HBI) | Baseline up to 52 Weeks | Clinical response is defined as a decrease in HBI score of \>=3 points from baseline. HBI score is used to measure the disease activity of CD. It consists of clinical parameters: general well-being (0-4, where higher score means lower well being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools, where higher scores indicating more severe disease. |
| Number of Bio-naïve Participants Reporting One or More Treatment-emergent Adverse Events | Baseline up to 52 Weeks | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With UC Achieving Durable Clinical Response Based on Partial Mayo Score | up to 52 weeks from start of another biological therapy | Durable clinical response is defined as clinical response at Week 104, where clinical response is defined as a decrease in the partial Mayo Score of at least 2 points and \>=25% from baseline, with an accompanying decrease in rectal bleeding subscore of \>=1 point from baseline or absolute rectal bleeding subscore of \<=1 point. Mayo score is an instrument designed to measure disease activity of UC. It consists of 3 subscores: stool frequency, rectal bleeding, and physician rating of disease activity, each graded from 0 to 3 with higher scores indicating more severe disease. These scores are summed to give a total score range of 0 to 9; where higher scores indicating more severe disease. Outcome measure is planned to be assessed in participants who failed on vedolizumab during the first 52 weeks and will switch to another biological therapy up to 52 weeks. |
| Percentage of Participants With UC Achieving Clinical Remission Based on Partial Mayo Score | up to 52 weeks from start of another biological therapy | Clinical remission is defined as a partial Mayo score of \<=2 with no individual subscore \>1. Mayo score is an instrument designed to measure disease activity of UC. It consists of 3 subscores: stool frequency, rectal bleeding, and physician rating of disease activity, each graded from 0 to 3 with higher scores indicating more severe disease. These scores are summed to give a total score range of 0 to 9; where higher scores indicating more severe disease. Outcome measure is planned to be assessed in participants who failed on vedolizumab during the first 52 weeks and will switch to another biological therapy up to 52 weeks. |
| Percentage of Participants With CD Achieving Durable Clinical Response Based on Harvey-Bradshaw Index (HBI) | up to 52 weeks from start of another biological therapy | Durable clinical response is defined as clinical response at Week 104, where clinical response is defined as a decrease in HBI score of \>=3 points from baseline. HBI score is used to measure the disease activity of CD. It consists of clinical parameters: general well-being (0-4, where higher score means lower well being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools, where higher scores indicating more severe disease. Outcome measure is planned to be assessed in participants who failed on vedolizumab during the first 52 weeks and will switch to another biological therapy up to 52 weeks. |
| Number of Participants who Failed Vedolizumab Therapy Reporting One or More Treatment-emergent Adverse Events | up to 52 weeks from start of another biological therapy | — |
| Percentage of Participants With CD Achieving Clinical Remission Based on Harvey-Bradshaw Index (HBI) | up to 52 weeks from start of another biological therapy | Clinical remission is defined as total HBI score of \<=4 points. HBI score is used to measure the disease activity of CD. It consists of clinical parameters: general well-being (0-4, where higher score means lower well being), abdominal pain (0-3, higher score means more severe pain), number of liquid stools per day, abdominal mass (0-3, where higher score means presence of swelling in the abdomen), and complications (score 1 per item). Total score is the sum of individual parameters. The score ranges from a minimum score of 0 to no pre-specified maximum score as it depends on the number of liquid stools, where higher scores indicating more severe disease. Outcome measure is planned to be assessed in participants who failed on vedolizumab during the first 52 weeks and will switch to another biological therapy up to 52 weeks. |
Countries
Austria
Outcome results
None listed